Drug Profile
Simenepag
Alternative Names: AGN-210676Latest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Allergan
- Developer AbbVie
- Class Antiglaucomas; Carboxylic acids; Pyrrolidines; Small molecules
- Mechanism of Action Prostaglandin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Glaucoma; Ocular hypertension
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 14 Oct 2010 Investigation in Glaucoma in USA (unspecified route)
- 14 Oct 2010 Investigation in Ocular hypertension in USA (unspecified route)